Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (9358)	3/23/1999 9:50:00 PM
From: Cacaito	Respond to of 17367

Bpi is the solution. All the others will be adjuvants.

To: Robert S. who wrote (9358)	3/24/1999 2:56:00 AM
From: aknahow	Respond to of 17367

More on Barclay. Wonder what he thinks about BPI and XOMA??? This was posted several years ago. ESKIA: e-mail EndoCAb.ESKIA@virgin.net or fax/voice (44) (0) 131 454 9181 under development by Dr G Robin Barclay PhD, Midlothian, Scotland. e-mail: Robin_Barclay@compuserve.com or R.Barclay@virgin.net Latest edition: updated January 12, 1999 EndoCAb normal values Pre-op EndoCAb and clinical outcome in cardiac bypass surgery Endotoxin core structures: lipopolysaccharide (LPS) schematics Basis of EndoCAb ELISA * Instructions for ESKIA EndoCAb ELISA kit (PDF file) EndoCAb ELISA kit now available in USA My relevant published references * EndoCAb review ( PDF file) * Dissociation of circulating endotoxin from bacterial isolate by anti-LPS MAb (PDF file) Background to our Monoclonal Anti-LPS-core antibody project Production of monoclonal anti-LPS-core MAbs *Some files are in "portable document format" (PDF). If your browser is already configured to view PDF files, simply click on the link. If you need to download the free software to view or print PDF files, click on the "Get Acrobat Reader" icon below. Robin Barclay: personal summary I am a Clinical Research Scientist at the Scottish National Blood Transfusion Service (SNBTS) where I developed research on antibodies to Gram-negative endotoxin core (Endotoxin Core Antibodies: EndoCAb) in diagnosis and immunotherapy. While SNBTS no longer has a direct interest in developing this area, I maintain a personal interest and collaborations outside SNBTS. My other fields of interest (current in SNBTS): transfusion medicine, immunology, immunohaematology, flow cytometry, leucodepletion, prions and CJD. Summary of EndoCAb work At the Edinburgh Regional Transfusion Centre of the Scottish National Blood Transfusion Service (SNBTS) in the 1980's I developed an interest in the potential role of cross-reactive antibodies to the core region of endotoxin lipopolysaccharide (LPS) in protecting the host against the pathogenic effects of endotoxin, and their possible use in passive immunotherapy. We developed a relevant assay for endotoxin core antibody (EndoCAb), and showed that these antibodies are commonly present and readily detectable in plasma from healthy individuals, and have established normal ranges for IgG, IgM and IgA classes of EndoCAb. A number of studies have confirmed abnormal levels and perturbations of normal levels of EndoCAb in a variety of clinical conditions. Studies with EndoCAb-hyperimmune plasma, gammaglobulin and anti-LPS-core cross-reactive monoclonal antibodies (not to lipid A) have shown in vivo and in vitro activity against endotoxin pathogenesis. Such studies have strongly supported a potential role for these or similar antibodies as anti-endotoxin therapeutic agents, and have indicated a role for the EndoCAb assay in diagnosis, especially in predicting "at risk" clinical groups or cases. Despite a number of approaches with a variety of agents, therapeutic intervention in clinical endotoxaemia remains intractable. The failure of the anti-lipid A monoclonal antibodies to show efficacy in clinical trials in sepsis patients has depressed commercial interest and led to a general impression that anti-endotoxin antibodies have little therapeutic potential. However, other agents have not been successful. SNBTS has not attracted sponsorship, has not the resources, or continuing enthusiasm, to sustain research and development in endotoxin antibodies. I remain convinced that the EndoCAb ELISA has diagnostic potential, and that certain anti-endotoxin antibodies have very good clinical therapeutic potential, especially in selected patient groups. I wish to retain a personal, private interest in this area, to encourage and assist collaboration with anyone who is interested - or just curious. In this respect I represent only myself and my own opinions, not those of SNBTS. However, to promote SNBTS, who own the WN1 222-5 anti-LPS-core monoclonal antibody which was developed in collaboration with Sandoz, I should say that in my opinion WN1 222-5 is the only anti-endotoxin MAb that I have encountered which has neutralized all E.coli and Salmonella endotoxins in all of the in vitro and in vivo pre-clinical tests which were carried out in a number of different reputable laboratories, and that it deserves to be tested in an appropriate clinical trial. If you have general or specific questions, requests or proposals with regard to the EndoCAb ELISA, please contact ESKIA.